Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Gains from Sales and Divestitures (2017 - 2023)

Rhythm Pharmaceuticals (RYTM) has disclosed Gains from Sales and Divestitures for 6 consecutive years, with $581346.0 as the latest value for Q4 2024.

  • On a quarterly basis, Gains from Sales and Divestitures rose 170.6% to $581346.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $581346.0, a 170.6% increase, with the full-year FY2024 number at $581346.0, up 170.6% from a year prior.
  • Gains from Sales and Divestitures was $581346.0 for Q4 2024 at Rhythm Pharmaceuticals, up from $214837.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $581346.0 in Q4 2024 to a low of $27583.0 in Q4 2021.
  • A 4-year average of $245578.0 and a median of $186691.5 in 2022 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 474.8% in 2022, then surged 35.5% in 2023.
  • Rhythm Pharmaceuticals' Gains from Sales and Divestitures stood at $27583.0 in 2021, then surged by 474.8% to $158546.0 in 2022, then soared by 35.5% to $214837.0 in 2023, then surged by 170.6% to $581346.0 in 2024.
  • Per Business Quant, the three most recent readings for RYTM's Gains from Sales and Divestitures are $581346.0 (Q4 2024), $214837.0 (Q4 2023), and $158546.0 (Q4 2022).